Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06095557 · ClinicalTrials.gov registry record · NA
MCG Discovery Study in Emergency Departments
A NA study of NSTEMI - Non-ST Segment Elevation MI and ACS (Acute Coronary Syndrome), sponsored by SB Technology.
- Completed
- Registry status
- NA
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT06095557: Completed NA study of NSTEMI - Non-ST Segment Elevation MI and ACS (Acute Coronary Syndrome), sponsored by SB Technology.
NCT06095557 is a NA study of NSTEMI - Non-ST Segment Elevation MI and ACS (Acute Coronary Syndrome) that has completed, run by SB Technology. The registered enrollment target is 124 participants, below the 16,397-participant average among 4 other NSTEMI - Non-ST Segment Elevation MI trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06095557, a NA study of NSTEMI - Non-ST Segment Elevation MI and ACS (Acute Coronary Syndrome), has completed, sponsored by SB Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.
Primary Outcome
% Sandbox MCG data collected and suitable for analysis
Conditions Studied
Interventions
- DEVICE Sponsor MCG device
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2025-07-08 |
| Phase | NA |
What the finished NCT06095557 record still lists
NCT06095557 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 16,397-participant average among 4 other NSTEMI - Non-ST Segment Elevation MI trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with NSTEMI - Non-ST Segment Elevation MI appearing as the primary indexed condition, and to 1 intervention - of which Sponsor MCG device is the first listed.
NCT06095557 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06095557 about?
NCT06095557 is a clinical study titled "MCG Discovery Study in Emergency Departments". This prospective discovery study is designed to demonstrate the feasibility of using an unshielded, mobile MCG device in an Emergency Department (ED) setting. The main question it aims to answer is whether interpretable data can be reliably collected as part of an ED workflow.
What is the current status of trial NCT06095557?
This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2023-10-30. Estimated completion is 2025-07-08.
What conditions does trial NCT06095557 study?
This clinical trial studies the following conditions: NSTEMI - Non-ST Segment Elevation MI, ACS (Acute Coronary Syndrome).
What interventions are being tested in trial NCT06095557?
The interventions under investigation include: Sponsor MCG device (DEVICE).
Who is sponsoring clinical trial NCT06095557?
This trial is sponsored by SB Technology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06095557 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSTEMI - Non-ST Segment Elevation MI
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI